Substantially optically pure S-oxybutynin, or a pharmaceutically acceptable salt thereof, is administered as a treatment for asthma. Such treatment is provided while reducing the adverse effects associated with the administration of racemic oxybutynin.
TECHNICAL FIELD
This application claims the benefit of Provisional Application No. 60/135,069, filed May 20, 1999.
The present invention relates to methods for treatment of asthma using S-oxybutynin.